

PETER GUNZBURG APPOINTED NON EXECUTIVE DIRECTOR

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is delighted to announce the appointment of Peter Gunzburg as a Non-Executive Director effective 20 October 2025.

Mr Gunzburg brings over 40 years' experience as a public company director, stockbroker, and investor. He holds a Commerce Degree from the University of Western Australia and previously served as Chairman of BARD1 Life Sciences Limited (now INOVIQ Ltd) from 2016 to 2020.

Mr Gunzburg is currently Chairman of Metals X Limited (ASX: MLX) and a Non-Executive Director of London Stock Exchange listed First Tin Plc (LSE: 1SN). Mr Gunzburg has also previously been a director of Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and several other public companies.

His appointment follows a request by Tian An Medicare Limited, the cornerstone investor in INOVIQ's recent capital raise, as announced on 13 October 2025. Following his participation in the placement completed today, Mr Gunzburg holds 3.337m shares in IIQ.

IIQ Chairman David Williams said: *"We are pleased to welcome Mr Peter Gunzburg back to the INOVIQ Board as a non-executive director. As a Top 20 shareholder and former Chairman, Peter brings strong knowledge of our technology and strategic direction."*

Mr Gunzburg said: *"I am excited to rejoin the INOVIQ Board at this pivotal stage in the Company's growth. INOVIQ's next-generation exosome-based diagnostics and therapeutics are advancing toward key development and commercial milestones. The EXO-OC™ test is poised to become a leading solution for ovarian cancer screening, improving outcomes for women globally. Additionally, INOVIQ's CAR-exosome platform holds promise as a next-generation CAR therapy for hard-to-treat cancers."*

Authorised for release by the Company Secretary, Mark Edwards.

- ENDS -

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.